Quantcast

Latest Anti-diabetic medication Stories

2014-06-15 15:18:02

The Endocrine Society Study suggests metformin controls blood sugar more effectively in African-Americans African Americans taking the diabetes drug metformin saw greater improvements in their blood sugar control than white individuals who were prescribed the same medication, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM). An estimated 29 million Americans have diabetes. African Americans are twice as likely to...

2014-06-15 08:21:29

-- The average HbA1C reductions in patients treated with ITCA 650 for 6 months at the time of the interim analysis were -3.2%; patients at baseline had HbA1C levels between 10-12%. BOSTON, June 15, 2014 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced the highlights of a poster presentation at the 74(th) Scientific Sessions of the American Diabetes Association (ADA) held in San Francisco that contained the first 6-month data from an ongoing open-label phase 3 trial...

2014-06-14 12:20:53

SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- Data from a new phase 3 study demonstrated that once-daily Victoza(R) (liraglutide [rDNA origin] injection) provided greater glycaemic control versus placebo with no worsening of renal function in adults with type 2 diabetes and moderate renal impairment.[1],[2] The data were presented today at the 74th Annual Scientific Sessions of the American Diabetes Association (ADA) in San Francisco, CA. Renal impairment is one of the more...

2014-06-14 12:20:36

SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- New Phase 3a findings show IDegLira, the investigational once-daily single injection combination of insulin degludec and liraglutide, for the treatment of people with type 2 diabetes, maintained its glucose-lowering effect and confirmed safety evaluations for up to one year.[1] Findings from the 26-week extension of the DUAL(TM) I clinical trial programme were presented today at the 74th Annual Scientific Sessions of the American...

2014-06-14 12:20:29

Data also showed liraglutide 3 mg improved blood glucose control compared to placebo at 56 weeks SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- Today, primary results from SCALE(TM) Diabetes, a phase 3a clinical trial of liraglutide 3 mg, an investigational once-daily glucagon-like peptide-1 (GLP-1) analogue for chronic weight management, were presented for the first time at the 74th Annual Scientific Sessions of the American Diabetes Association (ADA) in San Francisco,...

2014-06-10 08:30:52

Phase 3 Study Results Across Different Patient Populations, Including Comparative Analyses with Sitagliptin and Health Economics Data, are Among 15 Accepted Presentations RARITAN, N.J., June 10, 2014 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today that 15 presentations on INVOKANA(®) (canagliflozin) will be made at the American Diabetes Association (ADA) 74(th) Scientific Sessions(®), June 13-17 in San Francisco. The presentations include long-term safety...

2014-05-27 12:27:43

Traditional Type 2 Diabetes Drug Attributes Continue to be Key Even as First-Line Treatment Paradigms Shift, According to Findings from Decision Resources Group BURLINGTON, Mass., May 27, 2014 /PRNewswire/ -- Decision Resources Group finds that Eli Lilly's insulin peglispro is set to become the clinical gold-standard in the treatment of patients with type 2 diabetes inadequately controlled with diet and exercise, when metformin is not a therapeutic option. Although metformin continues to...

2014-05-26 08:22:34

INVOKANA((TM) )offers a new approach to treatment TORONTO, May 26, 2014 /CNW/ - Janssen Inc. announced today that Health Canada has approved INVOKANA((TM) )(canagliflozin), an oral, once-daily prescription treatment used to lower blood glucose (sugar) levels in adults with type 2 diabetes.(1) INVOKANA((TM) )belongs to a new class of medications called sodium glucose co-transporter 2 (SGLT2) inhibitors that offers a novel approach to treating diabetes by increasing the loss of...

2014-05-21 10:42:05

Diabetologia New research published in Diabetologia (the journal of the European Association for the Study of Diabetes) shows that increasing severity of heart failure is associated with an increased risk of developing diabetes. The study is by Dr Malene Demant, Department of Cardiology, Copenhagen University Hospital Gentofte, Copenhagen, Denmark, and colleagues. A previous study by the same authors has shown an increased risk of diabetes in patients with heart failure following a...

2014-05-17 23:01:16

The Firm is investigating Byetta lawsuits on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis and thyroid cancer due to their use of the Type 2 diabetes medication. New York, New York (PRWEB) May 17, 2014 Byetta lawsuits (http://www.byettalawsuit.com) and other product liability claims involving a class of diabetes drugs called incretin mimetics continue to mount in a federal multidistrict litigation now underway in U.S. District Court, Southern District of...


Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.